comprehensive -WSS

comprehensive

author：hotspot 2025-09-28 22:28:31 - browse：68

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Hospitals owned by private equity see complications spike 25%

focus

WSS

Medicare has a new plan to address drug shortages

SNAP should offer more nutrition education

HCA sued by state AG for quality issues at Mission Health

Cosmetics set for new safety regulation. Why the industry is on board

Prime Medicine, Myeloid Therapeutics clash over genome

At Orexo, a ‘turning point’ for everything but digital health

hotspot

comprehensive

focus

Duchenne breakthrough therapy leaves behind pioneering families

HCA sued by state AG for quality issues at Mission Health

Wildfire smoke exposes gaps in outdoor worker protections

Why hospitals are withdrawing from US News rankings

Anesthesiologist group: stop taking Ozempic before surgery

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Jerome Adams on the need for new antivirals for Covid

Virtual care provider acquires bankrupt Pear's prescription apps

Hollywood unions extend contract negotiations for actors

Carvykti CAR

Wikipedia

Carvykti CAR

CRISPR gene editing developments we’re watching in 2024

A public scorecard can help hold safety

Listen: Wegovy in the brain & pivotal Alzheimer's data

Medicare to cover more brain scans for Alzheimer’s patients

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Wikipedia

focus

Wikipedia

leisure time